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Economics and Political Science, London, UKA B S T R A C TObjectives: To estimate costs and outcomes of increasing access to
bariatric surgery in obese adults and in population subgroups of age,
sex, deprivation, comorbidity, and obesity category. Methods: A
cohort study was conducted using primary care electronic health
records, with linked hospital utilization data, for 3,045 participants
who underwent bariatric surgery and 247,537 participants who did not
undergo bariatric surgery. Epidemiological analyses informed a prob-
abilistic Markov model to compare bariatric surgery, including equal
proportions with adjustable gastric banding, gastric bypass, and
sleeve gastrectomy, with standard nonsurgical management of obe-
sity. Outcomes were quality-adjusted life-years (QALYs) and net
monetary beneﬁts at a threshold of £30,000 per QALY. Results: In a
UK population of 250,000 adults, there may be 7,163 people with
morbid obesity including 1,406 with diabetes. The immediate cost of
1,000 bariatric surgical procedures is £9.16 million, with incremental
discounted lifetime health care costs of £15.26 million (95% conﬁdence
interval £15.18–£15.36 million). Patient-years with diabetes mellitusee front matter Copyright & 2016, International S
r Inc. This is an open access article under the CC
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y’s Campus, London SE1 1UL, UK.will decrease by 8,320 (range 8,123–8,502). Incremental QALYs will
increase by 2,142 (range 2,032–2,256). The estimated cost per QALY
gained is £7,129 (range £6,775–£7,506). Net monetary beneﬁts will be
£49.02 million (range £45.72–£52.41 million). Estimates are similar for
subgroups of age, sex, and deprivation. Bariatric surgery remains cost-
effective if the procedure is twice as costly, or if intervention effect
declines over time. Conclusions: Diverse obese individuals may
beneﬁt from bariatric surgery at acceptable cost. Bariatric surgery is
not cost-saving, but increased health care costs are exceeded by
health beneﬁts to obese individuals.
Keywords: bariatric surgery, cost-effectiveness analysis, diabetes
mellitus, obesity.
Copyright & 2016, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
The recent increase in obesity has been accompanied by a
disproportionate increase in people affected by severe and
morbid obesity [1]. People with morbid obesity are at increased
risk of diabetes, cardiovascular diseases, and depression, lead-
ing to the development of multiple morbidities at young ages
and heightened risk of cardiovascular mortality [2]. The term
bariatric surgery refers to the use of surgical procedures for the
control of body weight. It is becoming increasingly clear that
bariatric surgery has important effects on obesity-related
comorbidities, especially type 2 diabetes. These effects are not
exclusively mediated by changes in body weight. Bariatricsurgery is sometimes also referred to as metabolic surgery.
Bariatric surgery may offer important health beneﬁts to people
with severe and morbid obesity, including reductions in body
weight [3], remission of established type 2 diabetes [4], lower
incidence of type 2 diabetes [5,6] and other long-term conditions
[7], as well as reduction in mortality [3,8]. The evidence base,
however, is changing. Different types of surgical procedures are
evolving over time, with declining use of adjustable gastric
banding and increasing use of gastric bypass and sleeve gas-
trectomy procedures [9]. New evidence has also emerged con-
cerning longer term outcomes and costs [10,11] of bariatric
surgery, including effects on mortality [8], disease incidence
[5], and diabetes remission [12,13].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
BY license (http://creativecommons.org/licenses/by/4.0/).
linical Practice Research Datalink obtained under license from the
retation and conclusions contained in this report are those of the
imary Care and Public Health Sciences, King’s College London,
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remains controversial. Access to bariatric surgery is often limited
by health care systems. In the United Kingdom, approximately
10,000 bariatric surgery procedures are performed annually [14],
but there are more than 1 million individuals with morbid obesity
who could potentially beneﬁt from the procedure [15]. This
limited access to bariatric surgery may be related to perceptions
that obesity might sometimes be a “lifestyle choice” and that the
cost of surgery, and the resources required to offer it more
readily, might be difﬁcult to justify. Some studies suggest that
bariatric surgery may be cost-saving to health systems [16], but
this is not supported by empirical studies of health care utiliza-
tion after bariatric surgery [17]. A recent study concluded that
“bariatric surgery does not reduce overall health care costs in the
long-term” and suggested that “future studies should focus on
the potential beneﬁt of improved health and well-being of
persons undergoing the procedure rather than cost-savings” [17].
The purpose of the present research was to investigate the
potential population impacts of bariatric surgery used at scale for
severe and morbid obesity. We aimed to evaluate the cost-
effectiveness of bariatric surgery, comprising laparoscopic gastric
banding, gastric bypass, and sleeve gastrectomy procedures, in
comparison with standard nonsurgical health care management
of obesity. We also aimed to determine whether there were
population subgroups deﬁned by age, sex, socioeconomic posi-
tion, obesity category, and comorbidity for whom bariatric sur-
gery might be more, or less, cost-effective.Methods
Model Structure
A Markov model was used to conduct a cost-utility analysis to
compare a strategy in which all eligible participants received
bariatric surgery, with standard nonsurgical weightBMI <30 BMI 30-34 BMI 35-39 BMI ≥40
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Fig. 1 – Structure of the Markov model. BMI, bmanagement. Because the use of different bariatric surgical
procedures has changed rapidly in recent years [9], bariatric
surgery was assumed to comprise one-third each of three main
procedures—gastric banding, gastric bypass, and sleeve gastrec-
tomy. We did not aim to explore the comparative effectiveness of
different bariatric surgical procedures within the scope of this
research. The model structure (Fig. 1) included the main inﬂuen-
ces on costs and outcomes of bariatric surgery (see Table 1 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2016.08.734). Healthy subjects, referred to as “At Risk,” may
develop one of the disease states of interest, including diabetes
mellitus, coronary heart disease (CHD), stroke, or cancer. Partic-
ipants in each state were allowed to progress to depression, with
each main state divided into substates representing “not
depressed” and “depressed” [18]. The model was stratiﬁed by
body mass index (BMI) category, comprising morbid obesity,
severe obesity, simple obesity, overweight, and normal weight,
and allowed participants to transition between BMI categories.
In each BMI category, there were ﬁve disease states that were
divided into “depressed” or “not depressed” (Fig. 1). All states
might lead to death. There were 101 states included in the model
across two treatment conditions. Each state was further stratiﬁed
by single year of age and sex. The perspective of the model was
that of health care services and only health care costs were
included. A lifetime time horizon was used.Cohort Study Using Electronic Health Records
Data to populate the model were derived by an epidemiological
analysis of electronic health records data from two cohorts of
participants drawn from the general population registered with the
UK Clinical Practice Research Datalink (CPRD). The CPRD includes
electronic health records of participants registered with a nationally
representative sample of approximately 600 UK family practices.
Estimates for the incidence, prevalence, mortality, and costs
of health care utilization for each state in the model wereery
Complicaons of surgery
BMI <30 BMI 30-34 BMI 35-39 BMI ≥40
At Risk At Risk At Risk At Risk
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ody mass index; DM, diabetes mellitus.
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from CPRD who did not receive bariatric surgery. The cohort was
sampled from the May 2014 release of CPRD and included
patients who were registered with CPRD practices between
January 1, 2008, and December 31, 2013. A random sample of up
to 50,000 participants was sampled from each BMI category
including 18.5 to 25, 25 to 29, 30 to 34, 35 to 39, 40 to 44, and
45 kg/m2 or higher. The last two categories were combined for
analysis so as to treat morbid obesity as a single category.
Estimates by deprivation quintile were obtained for participants
with Indices of Multiple Deprivation 2010 (IMD 2010) quintile data
linked through patients’ postcodes. This deprivation index score
is a nationally produced summary measure of deprivation con-
structed from a weighted combination of metrics for deprivation
on the domains of income, employment, health, education,
access to services, environment, and crime. These represent a
broad range of social and material deprivations [19]. Incidence
and mortality rates were estimated in a time-to-event framework
using a Weibull model (see Table 2 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2016.08.734). The start of
the analysis was the date on which the practice joined CPRD or
the date on which the patient joined a CPRD general practice if
this was later; the end of the analysis was at the end of the
patient’s record in CPRD, or the death date or the comorbidity
start date if these were earlier. For analysis of incidence, cova-
riates were age, age-squared, sex, and BMI category. For analysis
of mortality, covariates also included each comorbidity category,
including diabetes, CHD, stroke, and cancer. This facilitated the
estimation of mortality probabilities for each comorbidity cat-
egory. The median duration of analysis time was 5.6 years
(interquartile range, 2.3–10.3 years). The prevalence of depression
was estimated from CPRD data for each state in the model [18].
Mortality was assumed to be independent of depression status.
Health care utilization was estimated for each state from CPRD
records with linked hospital episode statistics data, including use
of primary care (family practice consultations, telephone con-
sultations, home visits, and emergency and out-of-hours con-
sultations), secondary care (including hospital admissions,
outpatient visits, day case visits, and emergency visits), and
prescriptions as reported elsewhere [20]. The annual costs asso-
ciated with each state were estimated by multiplying the health
care utilization associated with the state by the costs of each unit
of health care, which were obtained from standard reference
sources for 2013 [21] (see Table 3 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2016.08.734). Costs for each pre-
scription record were obtained from RESIP UK (Chertsey, Surrey,
UK). Patient-level costs were estimated from CPRD records using
a two-part regression model as reported previously [18,20]. A
cohort of participants who underwent bariatric surgery was also
drawn from CPRD and used to evaluate baseline use of bariatric
surgery and associations with diabetes incidence, diabetes remis-
sion, and depression prevalence as reported previously [5,22].
Model Estimation
The probabilistic Markov model was estimated by cohort simula-
tion, implemented through a program written in R software (R
Foundation for Statistical Computing, Vienna, Austria) [23]. The
initial population had ages ranging from 20 to 74 years, and we
observed that there were few bariatric surgical procedures for those
older than 74 years in CPRD. The proportion of the start population
with morbidity was also informed by an analysis of a CPRD cohort.
All simulations were stratiﬁed by single year of age with the
initial population aging by 1 year per cycle. Participants exited the
model when they reached 100 years of age or died. Annual
transition probabilities for the model were obtained by sampling
from the beta-binomial distribution, using CPRD data as inputs.The costs associated with each state were sampled from the
gamma distribution with the predicted mean value estimated
from a two-part model as outlined earlier. Utilities for each state
were obtained from data published in a compendium of values [24]
(see Table 4 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2016.08.734). Utility values for each state were strati-
ﬁed by single year of age but were the same for men and women.
Utility values were sampled from the beta distribution. Total costs
and quality-adjusted life-years (QALYs) were obtained by summing
across the 81 cycles of the model included in each simulation.
Results are expressed as rates per 1,000 participants entering the
model. Mean costs and the 95% CI were obtained from the data for
1000 simulations. Costs and QALYs were discounted using a rate of
3.5%, but undiscounted values and values discounted at 1.5% are
also shown as sensitivity analyses [25]. Net monetary beneﬁts
(NMBs) and net health beneﬁts (NHBs) were estimated at threshold
values of £20,000 and £30,000 per QALY, respectively [25].
Intervention Effects and Costs of Bariatric Surgery
The effect of bariatric surgery was modeled as a reduction in disease
incidence and mortality (Table 1). The effect of bariatric surgery on
the incidence of diabetes was drawn from CPRD data analyses [5]
that gave results very similar to data from the Swedish Obese
Subjects Study [7]. Effects on incidence of CHD, stroke, and cancer
were also drawn from the Swedish Obese Subjects Study [7,26],
which showed a reduction in cancer incidence in women but not in
men [26]. The relative risk of mortality after bariatric surgery was
obtained from Arterburn et al. [8] and this relative risk was applied to
the estimation of mortality probabilities in each model state. The
effect on depression prevalence was drawn from CPRD data analyses
[22] and is also consistent with other reports. On the basis of CPRD
data analyses, 40% of patients with diabetes entered remission after
the procedure [27]. Bariatric surgery wasmodeled as being associated
with a positive impact on patient utility of equal weight to a two-unit
change in BMI category [4,28]. This effect, however, was modeled to
decline over time, according to year to the power 0.25, consistent
with the known reduction in the initial quality-of-life improvement
after bariatric surgery [29]. The costs of bariatric surgery were drawn
from National Health Service tariffs and included preoperative
weight management, the cost of the procedure, and postoperative
reviews (Table 1). Bariatric surgery was assumed to comprise one-
third each of gastric banding, gastric bypass, and sleeve gastrectomy.
The cost of leaks was included as an average cost across all patients
[30]. Two percent of patients were assumed to require repeat
procedures each year, slightly higher than the 1.2% observed in
CPRD records [9]. Mortality from surgery was estimated at 0.07%
from the National Bariatric Surgical Register report [14]. Costs of
health care utilization were estimated from CPRD (see Table 4 in
Supplemental Materials). Costs of health care utilization after bari-
atric surgery were determined by age, sex, and morbidity category,
and were not modeled as associated with body weight reduction,
consistent with the results of empirical studies [10,11].
Subgroup and Sensitivity Analyses
Subgroup analyses were performed to estimate costs and out-
comes separately for men and women, for separate age groups
and categories of deprivation, comparing the most- and the least
-deprived quintiles of deprivation. Sensitivity analyses were
performed to explore the effects of varying the unit costs of
bariatric surgery, including values 50% and 100% higher than the
base case, and of varying the discount rate including values of
0%, 1.5%, and 3.5%. These were conducted to also estimate
outcomes assuming that intervention effects after bariatric sur-
gery might diminish with time. This was implemented by allow-
ing intervention effects from bariatric surgery to diminish by year
Table 1 – Data for costs and effects of bariatric surgery.
Item Value Source
Preoperative weight management £1024 Tier 3 weight management program
Procedure cost £7015 NHS tariff: LAGB £3620; GBP £8713; sleeve gastrectomy £8713 (33% each procedure)
Postoperative review £875
Cost of leaks £250 Bransen et al. [30]
Total procedure cost £9164
Cost of re-operations £3620 NHS tariff (FZ05A)
Rate of re-operation 2% per year CPRD (unpublished analyses)
Operative mortality 0.07% NBSR [14]
Diabetes remission 40% CPRD [25]
Incidence (relative risk)
Diabetes mellitus 0.20 (0.13–0.30) CPRD [5]
CHD 0.67 (0.54–0.83) SOS [7]
Stroke 0.67 (0.54–0.83) SOS [7]
Cancer 0.58 (0.44–0.77) SOS [26] (women only)
Mortality (relative risk) 0.45 (0.36–0.56) Arterburn et al. [8]
Depression (relative risk)
Year 1 0.82 (0.78–0.87) CPRD [22]
Year 2 0.83 (0.76–0.90)
Year 3 0.87 (078–0.97)
Decrement in utility associated with BMI (kg/m2) category
25–29 0 Hakim et al. [28]
30–34 0.085
35–39 0.17
Z40 0.255
BMI, body mass index; CHD, coronary heart disease; CPRD, Clinical Practice Research Datalink; GBP, gastric bypass; LAGB, laparoscopic
adjustable gastric banding; NBSR, National Bariatric Surgical Register; NHS, National Health Service; SOS, Swedish Obese Subjects Study.
V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ]4to the power 0.25 or 0.50. The former implies that the effect of
bariatric surgery will decline by 44% over 10 years, whereas the
latter indicates that the intervention effect will decline by 68%
over 10 years. This is in addition to the modeled time-related
decline in utility beneﬁt from bariatric surgery described earlier.
A sensitivity analysis was also used to test intervention cost-
effectiveness for patients with severe obesity (BMI 35–39 kg/m2)
or with morbid obesity and diabetes.
The use of fully anonymized CPRD data was approved by the
Medicines and Healthcare products Regulatory Agency’s Inde-
pendent Scientiﬁc Advisory Committee (Protocol number 13_089).
Protocol: The protocol for the study has been published online at
http://www.nets.nihr.ac.uk/projects/hsdr/12500512 and http://www.
nets.nihr.ac.uk/__data/assets/pdf_ﬁle/0005/81806/PRO-12-5005-12.pdf.Results
The population entering the Markov model comprised 200,000
participants with a BMI of 40 kg/m2 or higher with equal numbers
of men and women (mean age 46 years; range 20–74 years). There
were 19% with diabetes mellitus and 4% with CHD, the remaining
having no chronic comorbidity (Table 2).
Bariatric surgery was associated with an increase in total life-
years, accumulated over the lifetime of participants entering the
model, of 6,097 per 1,000 participants entering the model (Table 2).
There was a substantial increase in the number of life-years lived
free from chronic comorbidities of 10,297 per 1,000. There was a
decrease in life-years lived with diabetes mellitus of 8,320 per 1,000.
There were modest increases in life-years lived with CHD, stroke,
and cancer after bariatric surgery because of the increase in the
population at risk for these conditions over the lifetime of themodel.The total undiscounted health care costs over a lifetime for
1,000 persons with morbid obesity were estimated to be £97.82
million in the absence of bariatric surgery and £126.84 million with
bariatric surgery (Table 3). The undiscounted incremental cost
associated with bariatric surgery was £29.01 million, or £15.26
million when discounted at 3.5%. The cost of the bariatric surgical
procedure is estimated to be £9.16 million per 1,000 participants,
and so it can be concluded that bariatric surgery is associated with
increased lifetime health care costs associated with greater lon-
gevity. This is reﬂected in the greater estimated discounted QALYs
after bariatric surgery of 14,509 per 1,000 persons compared with
12,367 in the absence of bariatric surgery. The net gain in
discounted QALYs from bariatric surgery was 2,142 per 1,000
persons. The estimated value for discounted cost per QALY gained
was £7,129 per QALY, with a 95% CI from 1,000 simulations of
£6,774 to £7,506 per QALY. If each QALY gained is valued at
£30,000, then the net beneﬁt associated with bariatric surgery
performed in 1,000 persons with morbid obesity is approximately
£49 million, or £28 million if a value of £20,000 per QALY is used.
Table 4 presents the results of the analyses in subgroups of the
population as well as those of the sensitivity analyses that varied
underlying assumptions. All estimates were discounted at 3.5%.
Incremental costs and QALYs were slightly lower in men than in
women, reﬂecting the general lower life expectancy in men, but
estimates of costs per QALY were similar in men and women.
Older participants generally incurred lower total costs and fewer
total QALYs, consistent with their shorter life expectancy, but
incremental costs and QALYs were higher as a result of the higher
absolute risk reductions obtained in a population at higher baseline
risk. Nevertheless, cost-effectiveness estimates were generally
consistent across age groups. Comparing the use of bariatric
surgery in the most and the least-deprived quintiles of deprivation,
total costs were higher and total QALYs were lower in the most-
Table 2 – Distribution of initial population and model outputs per 1,000 participants entering the model.
Measure Bariatric surgery No bariatric surgery Incremental value
Mean 95% CI
Initial population entering the model
Number 200,000 200,000 –
Age (y), mean (range) 46 (20–74) 46 (20–74) –
Men 100,000 100,000 –
Women 100,000 100,000 –
No morbidity 153,846 (77) 153,846 (77) –
Diabetes mellitus 38,462 (19) 38,462 (19) –
CHD 7,692 (4) 7,692 (4) –
Model outputs (rate per 1,000 persons entering the model)
Total person-years lived 41,869.28 35,772.21 6,097 6,022 to 6,171
No morbidity (person-years) 22,296.44 11,998.61 10,297 10,152 to 10,452
Diabetes mellitus (person-years) 9,434.01 17,754.62 8,320 8,502 to 8,123
CHD (person-years) 5,321.58 3,771.50 1,550 1,473 to 1,626
Stroke (person-years) 1,309.54 633.92 676 647 to 705
Cancer (person-years) 3,507.70 1,613.56 1,894 1,830 to 1,957
Depression (person-years) 4,393.11 4,385.58 8 8 to 23
Note. Figures are frequencies (column percent) except where indicated.
CHD, coronary heart disease; CI, conﬁdence interval.
V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ] 5deprived quintile but incremental costs and QALYs were similar in
each deprivation category as were cost-effectiveness estimates.
The model was run using an initial population with severe obesity
and the procedure was found to be only slightly less cost-effective
in this group with an estimated cost of £7,675 per QALY. When the
initial population was conﬁned to morbidly obese persons with
diabetes, the estimated cost per QALY was £6,176 (£5,894–£6,457).
Estimates of cost-effectiveness were sensitive to the cost of
the surgical procedure. Nevertheless, even when the cost of the
procedure was 100% higher than that in the base case (£18,328
instead of £9,164), bariatric surgery was cost-effective at £11,376Table 3 – Cost-utility analysis of bariatric surgery in mor
Measure Bariatric surgery No
Health care costs per 1,000 (£, millio
Not discounted 126.84
Discounted 1.5% 93.06
Discounted 3.5% 67.25
QALYs per 1,000
Not discounted 28,345
Discounted 1.5% 20,547
Discounted 3.5% 14,509
Cost (£) per QALY
Not discounted
Discounted 1.5%
Discounted 3.5%
NMB per 1,000 (£, millions)
£30,000 per QALY
£20,000 per QALY
NHB per 1,000 (QALYs)
£30,000 per QALY
£20,000 per QALY
NHB, net health beneﬁt; NMB, net monetary beneﬁt; QALY, quality-adjuper QALY. Simulations in which the procedure cost was set at 0
conﬁrmed that incremental health care costs remained positive.
When the intervention effect from bariatric surgery was allowed
to diminish markedly over time after the procedure, there was
only a modest impact on estimated cost-effectiveness (Table 4),
reﬂecting the smaller contribution made by discounted costs and
QALYs from later periods of follow-up.
Table 5 presents the estimates for a health care commissioning
organization with a population of 250,000. On the basis of prevalence
rates for England, there may be 7,163 individuals with morbid
obesity, of whom 1,406 may have diabetes. The cost of 1,000 bariatricbid obesity.
bariatric surgery Incremental value
Mean 95% CI
ns)
97.82 29.01 28.78–29.23
72.38 20.68 20.53–20.81
51.99 15.26 15.18–15.33
22,772 5,572 5,422–5,728
17,022 3,524 3,397–3,655
12,367 2,142 2,032–2,256
5,208 5,075–5,338
5,868 5,662–6,073
7,129 6,775–7,506
49.02 45.72–52.41
27.59 25.40–29.85
1,634 1,524–1,747
1,380 1,270–1,493
sted life-year.
Table 4 – Cost-utility analyses for subgroup and sensitivity analyses..
Condition Bariatric surgery arm Incremental Cost per QALY
Mean 95% CITotal costs
(£, millions)
Total QALY Incremental costs
(£, millions)
Incremental QALY
BMI Z 40 67.25 14,509 15.26 2,142 7,129 6,775–7,506
35–39 68.08 14,708 15.00 1,995 7,675 7,339–8,037
Sex
Male 63.99 14,332 14.97 2,087 7,188 6,662–7,796
Female 70.51 14,680 15.55 2,201 7,076 6,581–7,638
Age group (y)
20–34 68.18 17,153 13.62 1,866 7,344 6,478–8,421
35–54 70.79 15,030 15.00 2,139 7,027 6,511–7,569
55–74 59.49 11,545 17.01 2,355 7,230 6,862–7,613
Deprivation category
Least deprived 61.49 14,791 14.46 2,052 7,056 6,688–7,448
Most deprived 70.00 14,187 16.32 2,242 7,287 6,930–7,665
Diabetes BMI
Z40 68.47 14,468 15.04 2,437 6,176 5,894–6,457
Costs of procedure
50% higher 71.83 14,511 19.84 2,144 9,261 8,800–9,795
100% higher 76.41 14,512 24.42 2,148 11,376 10,763–11,950
Zero procedure cost 58.09 14,512 6.10 2,148 2,842 2,701–2,998
Decline of intervention effect over time
Year0.25 64.25 13,786 12.25 1,422 8,637 8,009–9,400
Year0.50 63.15 13,516 11.16 1,152 9,720 8,860–10,706
Note. Figures are expressed as rates per 1,000 persons entering the model except where indicated.
BMI, body mass index; QALY, quality-adjusted life-year.
V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ]6surgical procedures will be £9,164 million. Over the lifetime of
patients who undergo bariatric surgery, the total increase in health
care costs may be £15.26 million. If these procedures are divided
equally among patients with diabetes and those without diabetes,
there will be 112 fewer patients diagnosed with diabetes over 10
years and at least 200 patients with diabetes may enter remission.
The health gain amounts to 2,142 QALYs and, valued at £30,000 per
QALY, NHBs are expected to be £49 million.Table 5 – Implications of research for an HCO with a pop
Measure Estimate
Total population aged 20–74 y 250,000
Number with morbid obesity 7,163 (4,875 women
and 2,288 men)
Number with morbid obesity and diabetes 1,406 (763 women an
643 men)
Cost of 1,000 bariatric surgical procedures, with
50% in people with diabetes
£9.164 million
Total increase in health care costs over
patients’ lifetime
£15.260 million
Number of new cases of diabetes prevented
over 10 y
112
Number of diabetes cases in remission over
next 5 y
200
Health gain in QALYs over patients’ lifetime 2,142
NMBs over patients’ lifetime (£30,000 per QALY) £49 million
Number with morbid obesity if the HCO is
among the most deprived
10,813 (7,663 wome
and 3,150 men)
Number with morbid obesity if the HCO is
among the least deprived
4,413 (2,838 women
and 1,575 men)
BMI, body mass index; HCO, health care commissioning organization; NDiscussion
Main Findings
This research modeled the lifetime health beneﬁts and health
care costs from bariatric surgery. The results project substantial
increases in life-years and reductions in years lived withulation of 250,000.
Source
Prevalence of obesity from Health Survey for England 2011–
2013
d Prevalence of diabetes by BMI category from Health Survey for
England 2011–2013
Table 1
Table 4
[5]
[25]
Table 4
Table 4
n Prevalence of obesity by deprivation quintile from Health
Survey for England 2011–2013 combined
MBs, net monetary beneﬁts; QALY, quality-adjusted life-year.
V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ] 7diabetes. Bariatric surgery is expected to be associated with
increased health care costs arising from the costs of the proce-
dure, as well as increased lifetime health care costs associated
with increased life expectancy. When health beneﬁts and costs
are combined into a single metric, using accepted values of cost
per QALY, the use of bariatric surgery is expected to yield
substantial NMBs amounting, over a lifetime, to £49 million per
1,000 persons. NHBs, after allowing for additional costs, may
amount to 1,634 QALYs per 1,000 persons. Bariatric surgery has
similar cost-effectiveness in men and in women, at different ages
and in different deprivation categories. Bariatric surgery is also
expected to be cost-effective in individuals with severe obesity
(BMI 35–39 kg/m2). Bariatric surgery will be cost-effective even if
the cost of the procedure is twice as high as we have estimated,
or if the effect of the procedure declines over time so that only
32% of the initial effect remains after 10 years.
This research made a comparison between “bariatric surgery”
and “no bariatric surgery” as an intervention for severe obesity.
There are several bariatric surgical procedures in use at present.
Over the last 10 years there has been a dramatic reduction in the
use of adjustable gastric banding procedures, with an increase in
the use of gastric bypass and sleeve gastrectomy procedures [9].
Although gastric banding is associated with lower procedure
costs, there may be a higher rate of revisional surgery [9]. Gastric
banding also has smaller, and less well-maintained, effects on
body weight [3] and diabetes outcomes [27] than do gastric bypass
or sleeve gastrectomy procedures. Future research is required to
evaluate the comparative cost-effectiveness of different bariatric
surgical procedures. This will require improved long-term out-
come data for procedures that are presently in use. At present,
some of the longest follow-up data are from the Swedish Obese
Subjects Study in which most of the participants underwent the
vertical banded gastroplasty procedure, which is now less used.
Our sensitivity analyses incorporated the possibility that in
future bariatric surgery may be more costly than it is at present,
as would be the case if a higher number of gastric bypass or
sleeve gastrectomy procedures were performed, or that the
intervention effect decayed rapidly over time, or if a higher
number of banding procedures were performed. In either even-
tuality, bariatric surgery would remain highly cost-effective.
Comparison with Previous Studies
There have been several previous cost-effectiveness analyses of
bariatric surgery for morbid obesity. One of the most author-
itative was the 2009 study by Picot et al. [31]. Their study reported
a model in which weight loss after surgery was viewed as the
main mediator of longer term changes in health outcomes. The
study found that bariatric surgery was a cost-effective interven-
tion for morbid obesity, with incremental cost-effectiveness
ratios ranging between £2,000 and £4,000 per QALY gained over
a 20-year time horizon [31]. A more recent study suggested that
bariatric surgery may be cost saving for health care systems
through reduced morbidity [16], but this conclusion has been
disputed. Although bariatric surgery does not appear to generate
cost savings, its use is associated with substantial health gains
at costs that are well less than accepted thresholds for cost-
effectiveness.
This analysis updates previous studies by including those
surgical procedures that are presently used, including adjustable
gastric banding, gastric bypass, and sleeve gastrectomy. The
analysis also updated the costs of surgery to present-day values.
The present model incorporated direct evidence concerning the
long-term outcomes of bariatric surgery in contrast to previous
studies, which have used changes in intermediate measures of
surgical effect including body weight, blood pressure, and lipid
proﬁles to model the long-term outcomes of bariatric surgery.Our analysis recognized that the effects of surgery, particularly
those on diabetes, are not entirely weight-dependent and our
model therefore did not include weight change as an intermedi-
ate outcome. The model was informed by recent measures of the
effects of surgery on substantive long-term health outcomes and
health care costs, additionally informed by analysis of CPRD
electronic health records. In spite of this difference of approach,
our analyses are consistent with previous reports in showing that
bariatric surgery is likely to be very cost-effective. We do not ﬁnd
that bariatric surgery is cost saving. This would, however, not be
expected because it is unlikely for a procedure that reduces
mortality in a population that experiences a heavy burden of
morbidity to reduce lifetime health expenditures [17].
Study Limitations
This research was based on empirical data for disease incidence,
mortality, and costs of health care utilization estimated from the
electronic health records of a large sample of participants
managed in primary care in the United Kingdom between 2008
and 2013. The study drew on recently published and authoritative
estimates of the effects and costs of bariatric surgery with an
emphasis on those bariatric surgical procedures that are pres-
ently used. We have used conservative assumptions including
that costs of health care utilization after surgery are not asso-
ciated with weight loss; that any gain in utility associated with
BMI reduction declines rapidly over time; and that remission
from diabetes after surgery occurs in 40% of patients, as esti-
mated from CPRD, which is lower than levels observed in other
reported studies. We acknowledge that any model represents a
simpliﬁcation of reality. There are other forms of morbidity that
were not represented in the model. Nevertheless, the costs of
health care utilization from such conditions will have been
included in cost estimates from CPRD, which encompassed all
health care utilization. We included the major complications of
surgery including operative mortality, costs of leaks after surgery,
and re-operations in 2% of patients per year. There may be
additional costs associated with surgery but a sensitivity analysis
showed that even if total costs of surgery were to be twice as high
as estimated in the base case, bariatric surgery would still be
cost-effective. We modeled bariatric surgery as having a constant
effect in the postoperative period, but we showed that even if the
effects declined over time, the surgery would still be cost-
effective. The model adopted a lifetime perspective by using
age-speciﬁc estimates from the present time. The large sample
size yielded precise estimates even for advanced ages. We
acknowledge that age-speciﬁc mortality rates in future are likely
to be different from those observed today. We note that it is
possible that bariatric surgery may result in “spillover” effects or
positive externalities if beneﬁts are transmitted to other family
members. For example, lifestyle changes on the part of a mother
might have an impact on the obesity risk and health behaviors of
the entire family. These effects might be quantiﬁed and modeled
in future research.Conclusions
Bariatric surgery is highly cost-effective and substantial NHBs or
NMBs may be anticipated from wider use of bariatric surgical
procedures in patients with severe and morbid obesity. Similar
cost-effectiveness may be anticipated in diverse groups of obese
individuals including men and women, wide ranges of ages, and
different levels of deprivation. Morbid obesity shows strong
socioeconomic patterning, and consequently bariatric surgery
may have the potential to reduce obesity-related inequalities in
health if there is equitable patient selection. This is in contrast to
V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ]8presently available nonsurgical interventions for obesity, which
generally have only small and short-lived effects [32]. On the
basis of these results, increasing access to bariatric surgery may
be a justiﬁable choice for publicly funded health care systems but
cost savings are not anticipated. The potential demand for
bariatric surgery is, however, likely to greatly exceed plausible
levels of supply. A major concern remains that the social and
environmental drivers of the increase in morbid obesity should
not remain unchecked. As a “downstream” procedure, bariatric
surgery will not stem the global increase in obesity. The role of
surgery in treating disorders apparently rooted in individual
lifestyle is also questioned. There are also concerns relating to
the capacity of health services to deliver safe, high-quality
services for patients with severe and morbid obesity, which were
recognized in the national guidance on bariatric surgery. Never-
theless, bariatric surgery may often offer important health gains
at an acceptable level of investment.
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